737 completed, 368 recruiting, 248 terminated, 210 unknown. 891 Phase 2, 622 Phase 1, 218 Not applicable, 176 Phase 3, 46 Early Phase 1.
Follow this condition Literature Review of Squamous Cell Carcinoma of Head and Neck trials Research Report on Squamous Cell Carcinoma of Head and Neck
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab PANDA-VAC, Pembrolizumab - Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer | Phase 1 | Suspended | UNC Lineberger Comprehensive Cancer Center | 6 | 2027-05-20 | 2026-04-23 |
| Chemo-embolization for Head and Neck Cancer Cisplatin - SCCHN, Squamous Cell Carcinoma | Phase 2 | Withdrawn | University of Alabama at Birmingham | 2027-05-01 | 2025-04-27 | |
| Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma Biospecimen Collection, Camonsertib, Computed Tomography - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 39 | 2027-02-13 | 2026-09-03 |
| Quad Shot Versus Split Course Radiotherapy in Incurable Head and Neck Cancer Quad Shot Radiotherapy, Split Course Radiotherapy - Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck | Not applicable | Not yet recruiting | Instituto Nacional de Cancerologia, Columbia | 40 | 2027-01-01 | 2026-10-02 |
| Antitumor-B KAC PK Study Antitumor B KAC - Squamous Cell Carcinoma of the Oral Cavity | Phase 1 | Withdrawn | Medical College of Wisconsin | 2026-12-01 | 2025-03-18 | |
| Feasibility and Validation of an Automated AI-Enabled Deep Ultraviolet (DUV) Cytology Platform for Point-of-Care Oral Cancer Triage Deep UV-M and AI Cytology Triage - Oral Potentially Malignant Lesions, Oral Potentially Malignant Disorders | Not applicable | Not yet recruiting | Anh Le | 270 | 2026-12-01 | 2026-09-25 |
| Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) Pembroluzimab, Observation - HPV-positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Withdrawn | Dana-Farber Cancer Institute | 2026-12-01 | 2026-10-08 | |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Intralesional Chemotherapy (IC): Cisplatin + Epinephrine Cisplatin, Epinephrine injection, Laryngeal Biopsy - Laryngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | University of Miami | 20 | 2026-12-01 | 2026-08-26 |
| Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial Ruxolitinib, Pembrolizumab - Carcinoma, Squamous Cell of Head and Neck HNSCC | Phase 2 | Not yet recruiting | University Hospital, Basel, Switzerland | 66 | 2026-11-01 | 2026-10-20 |
| CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma 64Cu-DOTA-ECL1i - Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | Phase 2 | Recruiting | Washington University School of Medicine | 90 | 2026-10-31 | 2026-10-07 |
| A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. LNTH-2403 - Imaging, Colorectal Cancer | Phase 1 | Not yet recruiting | Radiopharm Theranostics, Ltd | 16 | 2026-10-30 | 2026-08-12 |
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-10-26 | 2026-10-21 |
| MTX-531-001 Phase 1 Study in Advanced Solid Tumors MTX-531 - Solid Tumors (Phase 1), HNSCC | Phase 1 | Not yet recruiting | MEKanistic Therapeutics, Inc. | 71 | 2026-10-20 | 2026-10-15 |
| ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCC Becotatug Vedotin (MRG003), Pucotenlimab, Cisplatin - Stage IVB Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Huashan Hospital | 40 | 2026-10-20 | 2026-09-28 |
| Multispectral Optoacoustic Tomography in Head and Neck Squamous Cell Cancer Multispectral Optoacoustic Tomography, Temperature Measurement - Head and Neck Squamous Cell Carcinoma | Not applicable | Suspended | University of Oklahoma | 100 | 2026-10-01 | 2026-08-18 |
| Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma Rimegepant, Tislelizumab, Nab-paclitaxel - Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (OPSCC) | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 220 | 2026-10-01 | 2026-09-10 |
| Hypofractionated Radiotherapy in Older Adults With Head and Neck Squamous Cell Carcinoma Hypofractionated Radiotherapy, Normofractionated Radiotherapy - Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck | Not applicable | Not yet recruiting | Assiut University | 60 | 2026-10-01 | 2026-09-29 |
| Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma Sintilimab, Nab-Paclitaxel, Carboplatin - Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma | Phase 3 | Not yet recruiting | caohaotian | 300 | 2026-10-01 | 2026-09-18 |
| Scheduled IV Fluids in the Supportive Management of Patients Undergoing Chemo-radiotherapy for Head and Neck Cancer Scheduled IV Hydration, Clinician Assessment-Based IV Hydration - Squamous Cell Carcinoma of Hypopharynx, Squamous Cell Carcinoma of Larynx | Not applicable | Not yet recruiting | West Virginia University | 180 | 2026-10-01 | 2026-08-25 |
Showing 20 of 1943. Sign in to see all of them.
Head and Neck Neoplasms (578) · Carcinoma, Non-Small-Cell Lung (294) · Melanoma (167) · Carcinoma, Squamous Cell (148) · Colorectal Neoplasms (137) · Salivary Gland Neoplasms (125) · Mouth Neoplasms (117) · Carcinoma, Renal Cell (116) · Neoplasm Metastasis (115) · Breast Neoplasms (107) · Neoplasms (104) · Triple Negative Breast Neoplasms (102) · Uterine Cervical Neoplasms (102) · Ovarian Neoplasms (96)
Neoplasms by Histologic Type (1941) · Neoplasms, Glandular and Epithelial (1941) · Neoplasms by Site (1939) · Carcinoma (1880) · Neoplasms (1839) · Carcinoma, Squamous Cell (1795) · Head and Neck Neoplasms (1365) · Respiratory Tract Diseases (409) · Respiratory Tract Neoplasms (385) · Stomatognathic Diseases (370) · Thoracic Neoplasms (327) · Lung Diseases (325) · Skin and Connective Tissue Diseases (315) · Skin Diseases (312) · Bronchial Neoplasms (300)
Cisplatin (291) · pembrolizumab (245) · Radiotherapy (174) · Cetuximab (171) · Carboplatin (130) · Docetaxel (113) · Paclitaxel (98) · Fluorouracil (97) · Nivolumab (88) · Radiotherapy, Intensity-Modulated (81) · Magnetic Resonance Spectroscopy (40) · Surgical Procedures, Operative (36) · durvalumab (36) · Drug Therapy (35) · Radiation (34)
National Cancer Institute (NCI) (75) · M.D. Anderson Cancer Center (40) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (25) · Dana-Farber Cancer Institute (24) · Vanderbilt-Ingram Cancer Center (24) · Radiation Therapy Oncology Group (23) · Groupe Oncologie Radiotherapie Tete et Cou (21) · Memorial Sloan Kettering Cancer Center (21) · Washington University School of Medicine (21) · Roswell Park Cancer Institute (18) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (18) · University Health Network, Toronto (18) · West China Hospital (17) · Pfizer (16) · University of Chicago (16)
United States (1069) · China (266) · France (208) · Spain (159) · Canada (158) · United Kingdom (137) · Italy (122) · Germany (111) · Australia (109) · South Korea (109) · Taiwan (108) · Belgium (95) · Japan (73) · Netherlands (73) · Poland (60)
Barbara Murphy, MD (10) · Yuankai Shi, MD (8) · Douglas Adkins, M.D. (7) · Douglas R Adkins, M.D. (7) · Corey J. Langer, MD (6) · Dan Zandberg, MD (6) · Eben Rosenthal, MD (6) · Tanguy Seiwert (6) · Athanassios Argiris, MD (5)
PMID 25057165, PMID 25081901, PMID 31420360, PMID 31679945, PMID 32665297, PMID 33538338, PMID 41343184, PMID 15128893, PMID 15128894, PMID 16161069, PMID 17960012, PMID 19557750, PMID 20530316, PMID 22749632, PMID 23996343, PMID 25979390, PMID 27718784, PMID 30548235, PMID 32017652, PMID 33243986, PMID 33300372, PMID 33605440, PMID 33720067, PMID 35091445, PMID 36897458, PMID 36923556, PMID 40511820, PMID 40855191, PMID 41044356, PMID 42201333, PMID 10924966, PMID 11560968, PMID 11784253, PMID 12357184, PMID 12499279, PMID 12525193, PMID 12525530, PMID 12543777, PMID 12719478, PMID 12738335, PMID 12788192, PMID 12927569, PMID 14508838, PMID 14529772, PMID 14630288, PMID 14645636, PMID 15033677, PMID 15331400, PMID 15452834, PMID 15534360
2023 (34), 2019 (17), P30CA068485 (13), U10CA032102 (12), 2017 (11), 2018 (11), P30CA012197 (10), 2016 (9), 2025 (9), 2014 (8), U10CA021115 (8), U10CA180868 (8), 2015 (7), P30CA006516 (7), U10CA180820 (7)